Multiple Sclerosis and Related Disorders

Assessing remibrutinib in patients with relapsing MS 0:38
Assessing remibrutinib in patients with relapsing MS
Xavier Montalban • 4 Apr 2022
Benefits of remote rehabilitation programmes for patients with MS 1:51
Benefits of remote rehabilitation programmes for patients with MS
Letizia Leocani • 4 Apr 2022
Addressing unanswered questions in MS at AAN 2022 0:50
Addressing unanswered questions in MS at AAN 2022
Xavier Montalban • 4 Apr 2022
Updates on inflammatory demyelinating diseases 2:20
Updates on inflammatory demyelinating diseases
Hans Lassmann • 27 Jun 2022
The inflammatory process in MS 2:14
The inflammatory process in MS
Hans Lassmann • 27 Jun 2022
Strategies to incorporate patient-reported outcomes into clinical practice in MS 2:09
Strategies to incorporate patient-reported outcomes into clinical practice in MS
Caroline Pot • 27 Jun 2022
Pathology of multiple sclerosis: unanswered questions 1:22
Pathology of multiple sclerosis: unanswered questions
Hans Lassmann • 27 Jun 2022
The contribution of neuropathology to multiple sclerosis research 1:09
The contribution of neuropathology to multiple sclerosis research
Hans Lassmann • 27 Jun 2022
Promising biomarkers in MS: serum NfL & GFAP 0:42
Promising biomarkers in MS: serum NfL & GFAP
Caroline Pot • 27 Jun 2022
The role of oxidative stress in MS lesions 1:53
The role of oxidative stress in MS lesions
Hans Lassmann • 27 Jun 2022
The gut-brain axis in multiple sclerosis 2:32
The gut-brain axis in multiple sclerosis
Caroline Pot • 27 Jun 2022
Precision medicine in MS and factors to consider when making treatment decisions 2:18
Precision medicine in MS and factors to consider when making treatment decisions
Augusto Miravalle • 8 Apr 2022
Classification of disease subtypes in MS 1:12
Classification of disease subtypes in MS
Augusto Miravalle • 8 Apr 2022
Next steps for the implementation of precision medicine in MS 1:19
Next steps for the implementation of precision medicine in MS
Augusto Miravalle • 8 Apr 2022
Emerging biomarkers in MS: the value of serum NfL 2:01
Emerging biomarkers in MS: the value of serum NfL
Augusto Miravalle • 8 Apr 2022
Diet quality and clinical progression in MS over 7.5 years of follow-up 7:00
Diet quality and clinical progression in MS over 7.5 years of follow-up
Steve Simpson-Yap • 29 Jun 2022
The content of VJNeurology is intended for healthcare professionals